Healthcare / Medical Instruments & SuppliesHKSE
$0.36
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $12.5M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$180M
P/E
N/A
•EV/EBITDA
505.2x
↑ROE
-10.2%
↓Gross Margin
11.9%
↓Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.4%
FCF CAGR
+21.2%
FCF margin
5.2%
FCF / Net income
-1.72x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $500.3M · net income $-15.1M · FCF $26.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $500.3M | $500.3M | $453.6M | $393.3M | $465.4M |
| Net Income | $-15.1M | $-15.1M | $-21.6M | $1.4M | $9.2M |
| EBITDA | $278000.00 | $278000.00 | $-7.3M | $14.2M | $21.1M |
| EPS | -0.03 | -0.03 | -0.04 | 0.00 | 0.02 |
| Gross Margin | 11.9% | 11.9% | 9.8% | 14.5% | 16.3% |
| Operating Margin | -2.1% | -2.1% | -5.3% | -3.3% | 1.5% |
| Net Margin | -3.0% | -3.0% | -4.8% | 0.4% | 2.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.08 | 0.08 | 0.01 |
| Current Ratio | 1.91 | 1.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $26.0M | $26.0M | $12.5M | $-20.3M | $14.6M |
| Returns | |||||
| ROE | -10.2% | -10.2% | -13.8% | 0.8% | 4.9% |
| Valuation | |||||
| P/E | — | — | — | 150.00 | 43.48 |
| EV/EBITDA | 505.23 | 505.23 | — | 14.38 | 16.85 |
| P/B | 1.21 | 1.21 | 0.77 | 1.15 | 2.14 |
| Growth & Yield | |||||
| Revenue Growth | 10.3% | 10.3% | 15.3% | -15.5% | — |
| EPS Growth | 30.3% | 30.3% | -1646.4% | -84.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+105.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.04 → -0.03
Residual
+105.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.